<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00979199</url>
  </required_header>
  <id_info>
    <org_study_id>EVINCI</org_study_id>
    <secondary_id>European Commission</secondary_id>
    <secondary_id>FPVII grant 222915</secondary_id>
    <nct_id>NCT00979199</nct_id>
  </id_info>
  <brief_title>Evaluation of Integrated Cardiac Imaging in Ischemic Heart Disease</brief_title>
  <acronym>EVINCI</acronym>
  <official_title>Evaluation of Integrated Cardiac Imaging for the Detection and Characterization of Ischemic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione C.N.R./Regione Toscana &quot;G. Monasterio&quot;, Pisa, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione C.N.R./Regione Toscana &quot;G. Monasterio&quot;, Pisa, Italy</source>
  <brief_summary>
    <textblock>
      Main purpose of the study:

      To comparatively assess the diagnostic performance of non invasive anatomical and functional
      imaging modalities to detect significant obstructive coronary artery disease as demonstrated
      at invasive coronary angiography and functional evaluation of coronary lesions (fractional
      flow reserve).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives of the study

        1. To test the accuracy of anatomical and functional non-invasive cardiac imaging in the
           diagnosis of IHD. To this purpose the &quot;anatomical&quot; information provided by CTA is
           obtained in every patient together with the &quot;functional&quot; information provided by stress
           radionuclide cardiac imaging (SPECT or PET), to assess myocardial perfusion, and/or by
           stress MRI or ECHO imaging to assess myocardial contraction. Non-invasive results are
           tested against invasive reference standards. The latter consists of invasive coronary
           angiography integrated by invasive measurement of fractional flow reserve (to assess the
           hemodynamic relevance of intermediate coronary stenoses).

        2. To test the accuracy of integrated models, including clinical variables, risk factors
           and circulating biomarkers, to predict significant obstructive coronary artery disease
           in patients with chronic angina-like symptoms. To correlate biohumoral profiles with the
           coronary anatomical-functional phenotype as obtained by non invasive imaging in the same
           patients. To reach these goals the clinical characterization of patients (collected
           before non-invasive imaging) and the laboratory characterization (that includes novel
           biomarkers of cardiovascular risk) are compared with patient characterization derived
           from non invasive &quot;anatomic-functional&quot; imaging and with invasive diagnosis of
           significantly obstructive coronary disease.

        3. To develop an advanced clinical and imaging reporting tool in cardiology. An informatics
           platform is developed to synthetically and clearly present the integrated clinical and
           imaging diagnostic profile of individual patients. A multimodal imaging reporting tool
           is developed including tools for &quot;image fusion&quot; of different imaging modalities (CT,
           SPECT, PET, MRI).

        4. To define the most cost-effective work-up for the diagnosis and characterization of IHD.
           To this purpose the costs and the procedural risks (including radiation exposure) of
           non-invasive and invasive diagnostic procedures are prospectively collected.
           Cost-benefit and cost-effectiveness analyses is conducted alongside the EVINCI-study
           clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of IHD at Invasive Coronary Angiography and FFR Measurement</measure>
    <time_frame>3 months from enrollment</time_frame>
    <description>The outcome measure is the number of participants who received the diagnosis of IHD at invasive coronary angiography coupled with FFR measurements (in case of intermediate coronary lesions).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost-benefit and Cost-effectiveness Analysis</measure>
    <time_frame>3 months</time_frame>
    <description>Different non invasive imaging modalities are compared in terms of a cost-effectiveness analysis where costs include direct and indirect costs incurred as a consequence of the use of each modality or combination of modalities and effectiveness is the diagnostic accuracy with invasive diagnosis of IHD as end-point.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">697</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Non invasive cardiac imaging</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention: Non invasive cardiac imaging. 'Anatomical' information provided by CTCA is obtained in every patient together with the 'functional' information provided by stress radionuclide cardiac imaging (SPECT or PET), to assess myocardial perfusion, and/or by stress MRI or ECHO imaging to assess myocardial contraction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non invasive cardiac imaging</intervention_name>
    <description>Non invasive cardiac imaging consists of CTCA combined with one Stress Imaging Test</description>
    <arm_group_label>Non invasive cardiac imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with intermediate (&gt;20%, &lt;90%) risk of IHD based on age,gender,symptoms and
             exercise stress test results

        Exclusion Criteria:

          -  Age &lt; 30 Yrs or &gt; 75 yrs

          -  Pregnancy (suspected or ascertained)

          -  LV Dysfunction (LVEF &lt; 35% by Echo or other method)

          -  Low (&lt; =20%) or high (&gt;=90%) probability of CAD

          -  Acute Coronary Syndrome

          -  Prolonged (&gt; 20 minutes) chest pain

          -  De novo or accelerated angina

          -  Hemodynamic or electrical instability

          -  Recent ST-T segment or T wave changes of ischemic nature

          -  Acute myocardial infarction with or without ST segment elevation

          -  Elevated serum cardiac markers of necrosis

          -  Known diagnosis of CAD

          -  Previously known myocardial infarction

          -  Previous PCI

          -  Previous CABG

          -  Persistent atrial fibrillation or advanced AV Block

          -  Asthma or chronic treatment with aminophylline

          -  Recent (&lt;6 months) cerebral ischemic attack

          -  Known significant carotid stenosis or vascular aneurisms

          -  Asthma or chronic treatment with aminophylline

          -  Active cancer

          -  Severe hypertension. Patients cannot withdraw therapy for 12 hours.

          -  Congenital heart disease

          -  Significant valvular disease

          -  Cardiomyopathy (e.g. DCM, HCM, ARVC, Amyloidosis)

          -  Inability to provide an informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danilo Neglia, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Toscana G. Monasterio, Pisa, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.Turku</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KAE Goeppingen</name>
      <address>
        <city>Goeppingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TUM</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Versilia</name>
      <address>
        <city>Viareggio</city>
        <state>Lucca</state>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniGE</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniNA</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNR</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGM</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIC</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huvhebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SERMAS</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZH</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QUEEN MARY Hospital London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RBHT</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.escardio.org/communities/EACVI/studies-registries/EVINCI/Pages/EVINCI-home.aspx</url>
  </link>
  <link>
    <url>http://cordis.europa.eu/fetch?CALLER=FP7_PROJ_EN&amp;ACTION=D&amp;DOC=1&amp;CAT=PROJ&amp;RCN=89944</url>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2009</study_first_submitted>
  <study_first_submitted_qc>September 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2009</study_first_posted>
  <results_first_submitted>April 23, 2014</results_first_submitted>
  <results_first_submitted_qc>June 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2014</results_first_posted>
  <last_update_submitted>June 19, 2014</last_update_submitted>
  <last_update_submitted_qc>June 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione C.N.R./Regione Toscana &quot;G. Monasterio&quot;, Pisa, Italy</investigator_affiliation>
    <investigator_full_name>Danilo Neglia</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>IHD</keyword>
  <keyword>CAD</keyword>
  <keyword>Non invasive imaging</keyword>
  <keyword>SPECT</keyword>
  <keyword>PET</keyword>
  <keyword>CMR</keyword>
  <keyword>Echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CTCA and PET or SPECT and ECHO or MRI</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="697"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="475"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="222"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CTCA and PET or SPECT and ECHO or MRI</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="475"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Diagnosis of IHD at Invasive Coronary Angiography and FFR Measurement</title>
        <description>The outcome measure is the number of participants who received the diagnosis of IHD at invasive coronary angiography coupled with FFR measurements (in case of intermediate coronary lesions).</description>
        <time_frame>3 months from enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non Invasive Cardiac Imaging</title>
            <description>All patients are submitted to non invasive cardiac imaging. 'Anatomical' information provided by CTA is obtained in every patient together with the 'functional' information provided by stress radionuclide cardiac imaging (SPECT or PET), to assess myocardial perfusion, and/or by stress MRI or ECHO imaging to assess myocardial contraction. All patients with at least one positive functional test undergo invasive coronary angiography to obtain the final diagnosis of IHD (Outcome measurement).</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnosis of IHD at Invasive Coronary Angiography and FFR Measurement</title>
          <description>The outcome measure is the number of participants who received the diagnosis of IHD at invasive coronary angiography coupled with FFR measurements (in case of intermediate coronary lesions).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cost-benefit and Cost-effectiveness Analysis</title>
        <description>Different non invasive imaging modalities are compared in terms of a cost-effectiveness analysis where costs include direct and indirect costs incurred as a consequence of the use of each modality or combination of modalities and effectiveness is the diagnostic accuracy with invasive diagnosis of IHD as end-point.</description>
        <time_frame>3 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Non Invasive Cardiac Imaging</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Severe chest pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Danilo Neglia</name_or_title>
      <organization>CNR Institute of Clinical Physiology, Pisa, Italy and Fondazione Toscana G. Monasterio, Pisa, Italy</organization>
      <phone>+390503152019 ext 2019</phone>
      <email>dneglia@ifc.cnr.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

